EA201691918A1 - Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения - Google Patents

Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения

Info

Publication number
EA201691918A1
EA201691918A1 EA201691918A EA201691918A EA201691918A1 EA 201691918 A1 EA201691918 A1 EA 201691918A1 EA 201691918 A EA201691918 A EA 201691918A EA 201691918 A EA201691918 A EA 201691918A EA 201691918 A1 EA201691918 A1 EA 201691918A1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinaz
methods
inhibitor
production
pharmaceutical compositions
Prior art date
Application number
EA201691918A
Other languages
English (en)
Other versions
EA031190B1 (ru
Inventor
Рейчел Л. Брейк
Вивиана Бозон
Чинг-куо Дз. Чоу
Джеймс К. Динунцио
Кэтрин М. Гелвин
Каруппиах Каннан
Юки Кодоно
Циньли Сюй
Original Assignee
Милленниум Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Милленниум Фармасьютикалз, Инк. filed Critical Милленниум Фармасьютикалз, Инк.
Publication of EA201691918A1 publication Critical patent/EA201691918A1/ru
Publication of EA031190B1 publication Critical patent/EA031190B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Изобретение относится к фармацевтической композиции, содержащей соединение 1 или его фармацевтически приемлемую соль, для лечения рака и способу ее получения. Изобретение также относится к введению фармацевтической композиции пациенту в соответствии с прерывистым режимом дозирования.
EA201691918A 2014-03-26 2015-03-26 Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения EA031190B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461970595P 2014-03-26 2014-03-26
US201462048527P 2014-09-10 2014-09-10
PK16215 2015-03-25
UY0001036046A UY36046A (es) 2014-03-26 2015-03-25 Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PCT/US2015/022792 WO2015148828A1 (en) 2014-03-26 2015-03-26 Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use

Publications (2)

Publication Number Publication Date
EA201691918A1 true EA201691918A1 (ru) 2017-02-28
EA031190B1 EA031190B1 (ru) 2018-11-30

Family

ID=57215543

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691918A EA031190B1 (ru) 2014-03-26 2015-03-26 Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения

Country Status (17)

Country Link
US (1) US10426782B2 (ru)
EP (1) EP3122334B1 (ru)
JP (1) JP6571105B2 (ru)
CN (1) CN106456787B (ru)
BR (1) BR112016022219B1 (ru)
CA (1) CA2943808C (ru)
CO (1) CO2016003340A2 (ru)
CR (1) CR20160483A (ru)
DO (1) DOP2016000254A (ru)
EA (1) EA031190B1 (ru)
EC (1) ECSP16084317A (ru)
ES (1) ES2744298T3 (ru)
GE (1) GEP20186932B (ru)
MA (1) MA39765A (ru)
PE (1) PE20170773A1 (ru)
UY (1) UY36046A (ru)
WO (1) WO2015148828A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405348B (zh) * 2014-12-23 2021-06-11 点疗法-1公司 Raf抑制剂与紫杉烷的组合
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
WO2017165491A1 (en) * 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Use of a pd-1 antagonist and a raf inhibitor in the treatment of cancer
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2021108616A1 (en) * 2019-11-27 2021-06-03 Dot Therapeutics-1, Inc. Solid dispersion of pan-raf kinase inhibitor
CA3200986A1 (en) * 2020-11-06 2022-05-12 Day One Biopharmaceuticals, Inc. Raf inhibitor for treating low grade glioma
JP2024507221A (ja) * 2021-02-19 2024-02-16 デイ ワン バイオファーマシューティカルズ， インコーポレイテッド Ｒａｆ阻害剤とｍｅｋ阻害剤の組合せ
WO2023049807A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Improved methods for preparing nanoparticle compositions containing histidine-lysine copolymers

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US5346994A (en) 1992-01-28 1994-09-13 Piotr Chomczynski Shelf-stable product and process for isolating RNA, DNA and proteins
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US20050220865A1 (en) 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
AU2006325658B2 (en) 2005-12-16 2010-04-08 Hanmi Science Co., Ltd. Solid dispersion comprising an active ingredient having a low melting point and tablet for oral administration comprising same
KR100767349B1 (ko) * 2006-08-01 2007-10-17 삼천당제약주식회사 페노피브레이트를 함유하는 경구용 약제 조성물 및 그의제조방법
US20100143481A1 (en) 2006-11-08 2010-06-10 Dinesh Shenoy Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2008114859A1 (ja) * 2007-03-22 2008-09-25 Astellas Pharma Inc. ピラゾール誘導体を含有する医薬組成物
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2010033179A1 (en) 2008-09-17 2010-03-25 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
US20130172375A1 (en) * 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
JP2015511632A (ja) * 2012-03-30 2015-04-20 武田薬品工業株式会社 メラノーマの治療におけるｒａｆ阻害剤およびｍｅｋ阻害剤の投与

Also Published As

Publication number Publication date
BR112016022219B1 (pt) 2022-09-27
CO2016003340A2 (es) 2017-02-17
CN106456787A (zh) 2017-02-22
DOP2016000254A (es) 2017-02-15
ECSP16084317A (es) 2018-05-31
ES2744298T3 (es) 2020-02-24
BR112016022219A2 (pt) 2018-07-10
CA2943808C (en) 2022-08-16
US10426782B2 (en) 2019-10-01
MA39765A (fr) 2017-02-01
EP3122334B1 (en) 2019-06-26
CA2943808A1 (en) 2015-10-01
GEP20186932B (en) 2018-12-10
JP2017511313A (ja) 2017-04-20
US20170173033A1 (en) 2017-06-22
WO2015148828A1 (en) 2015-10-01
UY36046A (es) 2015-10-30
PE20170773A1 (es) 2017-07-04
JP6571105B2 (ja) 2019-09-04
EA031190B1 (ru) 2018-11-30
CN106456787B (zh) 2020-12-18
EP3122334A1 (en) 2017-02-01
CR20160483A (es) 2017-04-27

Similar Documents

Publication Publication Date Title
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
EA201692480A1 (ru) Фармацевтическая композиция
PH12016502352A1 (en) Pharmaceutical composition
EA202090683A3 (ru) Способы и композиции для лечения рака
TW201613578A (en) Pharmaceutical combinations
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
BR112015031417A8 (pt) forma de dosagem farmacêutica, composição farmacêutica, métodos para tratamento de um paciente com necessidade de cisteamina e para preparo de uma forma de dosagem
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
BR112017004580A2 (pt) composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
MX2017012022A (es) Compuestos organicos.
EA201691796A1 (ru) П-замещенные асимметричные мочевины и их применение в медицине
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU